Fosbretabulin

Drug Profile

Fosbretabulin

Alternative Names: CA4DP; CA4P; Combretastatin A-4 phosphate - Mateon Therapeutics; Combretastatin A4 prodrug; Combretastatin-A4; Combretastatin-A4 phosphate; CRC 87-09; CRC-98-09; CS-A4; Fosbretabulin disodium; Fosbretabulin tromethamine; NSC-613729; Zybrestat®

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics; National Cancer Institute (USA); OXiGENE; University of Kentucky
  • Class Antineoplastics; Combretastatins; Small molecules; Stilbenes
  • Mechanism of Action Cadherin 5 inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioma; Thyroid cancer; Neuroendocrine tumours
  • New Molecular Entity Yes
  • Available For Licensing Yes - Eye disorders; Ovarian cancer

Highest Development Phases

  • Phase II/III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Gastrointestinal cancer; Neuroendocrine tumours
  • Preclinical Leukaemia; Malignant carcinoid syndrome; Pancreatic cancer
  • Suspended Age-related macular degeneration; Thyroid cancer
  • No development reported Choroidal neovascularisation; Colorectal cancer; Head and neck cancer
  • Discontinued Diabetic retinopathy; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 16 Aug 2017 Updated interim efficacy and adverse events data from the phase II/III FOCUS trial in Ovarian cancer released by Mateon Therapeutics
  • 28 Jun 2017 Interim preclinical data from a combination study released by Mateon Therapeutics
  • 12 Jun 2017 Updated adverse events data from the phase Ib/II trial in Ovarian cancer released by Mateon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top